Australia's largest stock trading and investment forum Australia's #1 stock forum

RAD

0.00%

2.7¢ radiopharm theranostics limited

I'm surprised no one else has commented on this.Incredible...

First 3 Last

Share
Profile

Follow
Tradingdreamz88

5,110 Posts.

963

28/08/24

12:29

Post #: 75413241
Share

Originally posted by Steini: ↑

He was supposed to buy 75m shares for 4c each. And that should have kept him easily above 5%. Not 100% sure but he had at least 90m shares held under Kilinwata Investment plus 75m should be at least 165m. Even at 2b SoI that would be more than 5%. Looks like he did not participate as indicated.

If so, then we will definitely get a new chairman as Lantheus & Co got much bigger sub holdings. Has he given up control and would that mean he is retiring from RAD?

GLTA

Expand

I'm surprised no one else has commented on this.

Incredible form
Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 3 Last

Add RAD (ASX) to my watchlist

(20min delay)
Last 2.7¢		Change 0.000(0.00%)		Mkt cap ! $58.66M

Open	High	Low	Value	Volume
2.7¢	2.7¢	2.6¢	$118.5K	4.468M

Buyers (Bids)

No.	Vol.	Price($)
5	154230	2.6¢

Sellers (Offers)

Price($)	Vol.	No.
2.7¢	627213	3

View Market Depth

No.	Vol.	Price($)
5	154230	0.026
8	1195000	0.025
4	444000	0.024
5	615075	0.023
1	500000	0.022

Price($)	Vol.	No.
0.027	627213	3
0.028	433333	2
0.029	303448	2
0.030	935714	3
0.031	551676	3

Last trade - 16.10pm 04/10/2024 (20 minute delay)

RAD (ASX) Chart

I'm surprised no one else has commented on this.Incredible...

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I&apos;m surprised no one else has commented on this.Incredible...

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'm surprised no one else has commented on this.Incredible...